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Abstract
Background: Mucormycosis is a rare and life-threatening invasive fungal infection. Pulmonary mucormycosis
commonly occurs in patients with severe neutropenia. Typically, pulmonary mucormycosis causes tissue necrosis
resulting from angioinvasion and subsequent thrombosis, so most cases can occur with necrotizing pneumonia
and/or hemoptysis. Some complex cases may invade adjacent organs, such as the mediastinum, pericardium, and
chest wall. However, to the best our knowledge there is little known regarding bronchoesophageal fistula due to
pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia. We present a case report
about this unusual presentation.
Case presentation: A 51-year-old Korean man was diagnosed as having acute myeloid leukemia and received
induction chemotherapy. After prolonged severe neutropenia, he complained of coughing with aspiration. Imaging
showed a bronchoesophageal fistula with extensive necrotizing pneumonia in the middle and lower lobes of his
right lung. Bronchoscopy showed near total tissue necrosis in the middle lobe of his right lung, creating an orifice.
A bronchial scope was passed through and was able to be connected with his esophagus; a bronchial wall biopsy
was performed. Esophagoscopy revealed a large linear defect of his esophageal wall 30 cm from the incision that
may have connected with the bronchus. A bronchial biopsy showed typical hyphae with necrotic tissue, indicating
pulmonary mucormycosis. He was given amphotericin B, and a wide excision of lung and esophagus was planned.
However, he suddenly died due to massive hemoptysis.
Conclusion: Here we present an extremely rare case of bronchoesophageal fistula with severe necrotizing
pneumonia due to pulmonary mucormycosis.
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Background
Chemotherapy-induced immunosuppression has led to
an increase in the incidence of fungal infections. Mucor-
mycosis is a rare and life-threatening invasive fungal in-
fection caused by fungi of the Zygomycetes class and
Mucorales order. Pulmonary mucormycosis commonly
occurs during chemotherapy-induced neutropenia often
associated with hematologic malignancy and usually pro-
gresses rapidly [1–3].
Case presentation
A 51-year-old Korean man was diagnosed as having acute
myeloid leukemia (acute myelomonocytic leukemia, M4)
with normal karyotype (46,XY). An initial complete blood
count (CBC) showed a white blood cell (WBC) count of
65.29×109/L, neutrophils 22 %, monocytes 67 %, hemo-
globin 8.7 g/dL, and platelet count 18×109/L. He received
induction chemotherapy of cytarabine (100 mg/m2 body
surface area on days 1 to 7) and idarubicin (12 mg/m2
body surface area on days 1 to 3).
On day 3 of therapy, when his WBC count reached its
nadir, and his absolute neutrophil count was 277/mL,
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filgrastim was immediately started. He had no signs of
infection, including fever, coughing, or diarrhea.
On day 13 of chemotherapy, he developed a neutro-
penic fever and complained of right pleuritic chest pain
with productive coughing and sticky sputum. A chest X-
ray showed lobar infiltration of the lower lobe of his right
lung. Antibiotics were subsequently changed from prophy-
lactic ciprofloxacin to meropenem and vancomycin.
On day 17 of chemotherapy, his neutropenic fever per-
sisted, and a chest X-ray showed increased infiltration of
his right lung field with pleural effusion. Laboratory data
were as follows: WBC count of 0.31 (103/mm3), neutro-
phils 51.2 %, lymphocytes 32.2 %, absolute neutrophil
count of 150, hemoglobin 7.3 g/dL, platelet count 34
(103/mm3), C-reactive protein 27.1 mg/dL (normal range
0 to 0.5), and procalcitonin 1.74 ng/mL (normal range 0
to 0.5). We performed pleural puncture and pleural fluid
examinations. Analysis of his right-side pleural fluid in-
dicated an exudative type. His pleural fluid had a WBC
count of 670 (42 % neutrophils), total protein 4.75 g/dL,
and lactate dehydrogenase (LDH) 1183 IU/L. The results
of pleural galactomannan and acid-fast bacilli tests were
negative, but the pleural fluid culture grew Enterococcus
faecium that was resistant to vancomycin.
His antibiotic regimen was switched to meropenem
and linezolid, and the prophylactic antifungal agent (oral
fluconazole) was changed to caspofungin, an empiric
therapy, due to the prolonged neutropenia.
On day 19 of the therapy, his WBC count recovered to
an absolute neutrophil count of 3360. A bone marrow
biopsy was performed to confirm response to induction
chemotherapy, and biopsy results indicated complete
remission.
Nevertheless, his fever persisted, a chest X-ray showed
no change in lung consolidation, and he complained of a
cough that became more severe after swallowing.
An esophagram was subsequently performed and re-
vealed an approximately 2 cm filling of a fistula at the
mid-esophagus and the right bronchus intermedius
(Fig. 1).
Further evaluations with a chest computed tomog-
raphy (CT) as well as esophagoscopy and bronchoscopy
were recommended. Chest CT imaging showed extensive
necrotizing pneumonia of his right lung and bilateral
pleural effusion predominantly on the right side. In
addition, a small, linear, walled air collection was noted
just medial to the bronchus intermedius tracking towards
his esophagus, a finding suspicious for a bronchoesopha-
geal fistula (Fig. 2).
Flexible bronchoscopy showed mucosal hyperemia in
his right upper bronchus and brownish extensive tissue
necrosis in the middle lobe of his right lung (Fig. 3). Sub-
sequent biopsy and culture were performed.
Esophagoscopy revealed a large linear defect of his
esophageal wall 30 cm from the upper incision that per-
haps connected with the bronchus (Fig. 4).
A bronchoscopic biopsy showed broad and pleomorphic
hyphae with necrotic debris. The hyphae appeared non-
septate. Branches arose haphazardly, often at right an-
gles. These findings suggested pulmonary mucormycosis
(Fig. 5). Lung tissue was cultured; unfortunately, the speci-
men was inadequate.
The antifungal agent was changed from caspofungin
to liposomal amphotericin B (®AmBisome) at a starting
dose of 5 mg/kg daily. A wide excision of his lung and
perhaps of his esophagus was planned, as continued
consolidation chemotherapy was required to treat the
acute myeloid leukemia. However, he suddenly died due
to massive hemoptysis. A timeline for our patient is
given in Table 1.
Discussion
Mucormycosis is a relatively rare infection compared to
species such as Candida and Aspergillus. The prevalence of
mucormycosis is estimated at 1.7 cases per million people
per year according to one population-based study and has
Fig. 1 a, b Barium esophagram shows the fistula between the esophagus and the right bronchus intermedius (white arrows)
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ranged from 1 to 5 cases per 10,000 according to some
autopsy studies [4–6]. Mucormycosis is found in 0 to 8.3 %
cases of acute leukemia, and the most common pattern of
presentation is pulmonary mucormycosis [1, 7, 8].
Both mononuclear and polymorphonuclear phagocytes
of normal hosts kill Mucorales by generating oxidative
metabolites and cationic peptides known as defensins. The
most important conditions predisposing to mucormycosis
include hematologic malignancy, stem cell transplantation,
prolonged and severe neutropenia, poorly controlled dia-
betes mellitus with or without diabetic ketoacidosis, iron
overload, major trauma, prolonged corticosteroid use, illicit
Fig. 2 a Chest X-ray on the day of admittance. b Chest X-ray on day 17 of therapy showing a newly appearing infiltration of right lung with
pleural effusion. c, d Chest computed tomography scan on day 19 of the therapy shows air bronchograms, diffuse consolidation with necrotic
low attenuation of right lung (c), and bronchoesophageal fistula (white arrow; d)
Fig. 3 a Flexible bronchoscopy showing hyperemic mucosa on right upper bronchus with white exudate and b brownish necrotic tissue on the
middle lobe of his right lung. Obtained tissue was necrotic
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intravenous drug use, neonatal prematurity, and malnour-
ishment [1–3, 9, 10].
Based on the clinical presentation and involvement,
mucormycosis can be divided into the following six
major clinical forms: (1) rhinocerebral, (2) pulmonary,
(3) cutaneous, (4) gastrointestinal, (5) disseminated, and
(6) uncommon rare manifestations, such as endocarditis,
osteomyelitis, peritonitis, and renal infection. Among
them, pulmonary mucormycosis occurs most often in
patients with neutropenia undergoing chemotherapy or
stem cell transplantation [11, 12].
The clinical signs and symptoms of pulmonary mucor-
mycosis are nonspecific and cannot be easily distinguished
from pulmonary aspergillosis. It usually presents with nec-
rotizing pneumonia, and the symptoms include prolonged
high-grade fever and other various findings including
cough, chest pain, dyspnea, and hypoxia. In particular,
pulmonary mucormycosis results in tissue necrosis
due to angioinvasion and subsequent thrombosis; if a
major blood vessel is involved, it can lead to hemoptysis.
Multiple reports show that in severe cases, it can invade
adjacent organs, such as the mediastinum, pericardium,
and chest wall [11–15].
The most frequent radiographic findings include infil-
tration, consolidation, nodules, cavitations, atelectasis,
effusion, posterior tracheal band thickening, hilar or me-
diastinal lymphadenopathy, and even normal findings.
However, these findings are indistinguishable from those
of pulmonary aspergillosis [16–18]. Therefore, the best
mode of diagnosis for pulmonary mucormycosis is
bronchoscopic or percutaneous lung biopsy. Ultim-
ately, a confirmatory diagnosis of mucormycosis is
based on both: (1) histopathological findings of tissue
invasion by hyphae with tissue necrosis resulting from
angioinvasion and subsequent thrombosis and 2)
cultures isolating pathogens of the order Mucorales
[1, 12, 19].
Other than histopathology, there are no biomarkers to
identify this disease. Therefore, the high mortality
observed in pulmonary mucormycosis may be related to
delays in the diagnosis. Another cause of high mortality
is rapid progression, extensive involvement, severe under-
lying conditions, and limited available therapy. The overall
mortality rate in pulmonary mucormycosis is high (76 %);
it is even higher in severely immunosuppressed patients
[1, 12, 20].
Fig. 4 a Esophagoscopy showing a large defect of the esophageal wall 30 cm from the upper incision and b brownish necrotic tissue
Fig. 5 a, b Bronchoscopic biopsy histology shows many fungal hyphae with necrotic debris. The hyphae appear non-septate and thin-walled.
Most hyphae appear broad-branching, with some hyphae appearing to branch at right angles (black arrow) upon staining with hematoxylin and
eosin (×400)
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Treatment of pulmonary mucormycosis is difficult and
often delayed, as described above. Important factors for
successful treatment of mucormycosis is rapidity of diag-
nosis, reversal of the underlying predisposing factor (if
possible), appropriate surgical debridement of infected
tissue, and appropriate antifungal therapy. Small focal
lesions can often be surgically excised before they dis-
seminate or progress to involve critical structures. The
only recommended antifungal agents are members of
the polyene class, including amphotericin B deoxycholate
and its lipid derivatives.
Therefore, the main treatment for pulmonary mucormy-
cosis is immediate surgical resection of the infected tissue,
followed by administration of amphotericin B [21–24].
Typically, an esophagopulmonary fistula may occur as
a complication of infectious disorders, foreign body in-
gestion, a complication of intubation with cuff-related
tracheal injury, cancer, or congenital anomalies. Pulmon-
ary mucormycosis may invade organs adjacent to the
lungs, such as the mediastinum, pericardium, chest wall,
or even the esophagus. However, to the best of our
knowledge, little is known regarding bronchoesophageal
fistula due to pulmonary mucormycosis [25–28].
Conclusions
Esophagopulmonary fistula is a rare but serious condi-
tion. It can occur as a complication of infections but, to
the best of our knowledge, there has been no case report
of bronchoesophageal fistula due to pulmonary mucor-
mycosis. This is the first case report of such an unusual
presentation.
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